• 1
    Ladage D, Brixius K, Hoyer H, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720724.
  • 2
    Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511514.
  • 3
    Dessy C, Moniotte S, Ghisdal P, et al. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004;110:948954.
  • 4
    Garban HJ, Buga GM, Ignarro LJ. Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol. 2004;43:638644.
  • 5
    Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677684.
  • 6
    Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:12511257.
  • 7
    Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:37953801.
  • 8
    Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:25882605.
  • 9
    Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:1015.
  • 10
    Kocyigit I, Kaya MG, Orscelik O, et al. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol. 2012;36:1118.
  • 11
    Peralta CA, Norris KC, Li S, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012;172:4147.
  • 12
    Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:12131225.
  • 13
    Schram MT, Henry RM, van Dijk RA, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension. 2004;43:176181.
  • 14
    Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:11221128.
  • 15
    Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663667.
  • 16
    Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:22272236.
  • 17
    Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893898.
  • 18
    Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19:214219.
  • 19
    Manolis AJ, Iraklianou S, Pittaras A, et al. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens. 2005;18:1822.
  • 20
    Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23:551556.
  • 21
    Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118123.
  • 22
    Warmack TS, Estes MA, Heldenbrand S, Franks AM. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009;43:20312043.
  • 23
    Davies J, Carr E, Band M, et al. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? J Renin Angiotensin Aldosterone Syst. 2005;6:151153.
  • 24
    Khan BV. The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function. Ther Adv Cardiovasc Dis. 2011;5:241273.
  • 25
    Akgullu C, Ozdemir B, Yilmaz Y, et al. Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease. Acta Cardiol. 2008;63:467471.
  • 26
    Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8:638644.
  • 27
    Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431436.
  • 28
    Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:309315.